Creating new targeted drugs for cancer treatment
Official title: Developing a Suite of Targeted Anticancer Drugs
Funded at University of Illinois at Urbana-Champaign · NIH-10931498 · Data updated 2026-11-12
This study is working on creating special cancer drugs that are designed to fit the unique problems in each patient's tumor, so that people with different types of cancer can get more effective treatments just for them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Urbana-Champaign NIH-funded |
| Lab location | 1 site (Champaign, United States) |
| Project start | September 20, 2023 |
| Project end | August 31, 2030 |
| Funding year | 2024 |
| Award (this year) | $761,240 |
| NIH project number | 5R35CA283859-02 |
| Project ID | NIH-10931498 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients whose tumors have identifiable molecular defects that could be targeted by new drugs.
✕Less likely to help
Patients with cancer types that do not have identifiable molecular defects or those for whom no targeted therapies are available may not benefit from this research.
What this research studies
This research focuses on developing a range of targeted anticancer drugs that can be matched to specific molecular defects in patients' tumors. By utilizing advanced techniques in drug discovery, including compound synthesis and sophisticated animal models, the project aims to identify and create drugs that are tailored to treat various cancer subtypes. The approach emphasizes personalized medicine, where treatment is based on the unique characteristics of a patient's cancer, potentially leading to more effective therapies.
Why it matters
Potential benefit: If successful, this research could lead to new, personalized cancer treatments that are more effective for patients with specific tumor profiles.
How similar studies have gone: Previous research has shown success in developing targeted therapies for specific cancer mutations, indicating that this approach has potential for further advancements.
Where this research is happening
-
University of Illinois at Urbana-Champaign
Champaign, United States Active
Researchers
- Principal investigator: Hergenrother, Paul — University of Illinois at Urbana-Champaign
- Study coordinator: Hergenrother, Paul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.